drugset
drugset / Trial / NCT01147458

A Study Of The Safety And Efficacy Of PF-04191834 In Patients With Osteoarthritis Of The Knee

NCT01147458 ↗

Phase 2 Terminated 190 enrolled Pfizer
RandomizedCrossoverDouble-blindTreatment

Summary

PF-04191834 works in animal models by inhibiting one of the enzymes, 5-lipoxygenasein which is involved in the pathway that causes inflammation and pain. The purpose of this study is to test how effective, safe and tolerated PF-04191834 is in patients with osteoarthritis of the knee by itself or with naproxen, particularly to test if patients have less pain.

Timeline

Start
2010-07
Primary completion
2011-02
Completion
2011-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Naproxen Small molecule 500 mg Oral
Subject PF-4191834 Small molecule 600 mg Oral

Indications

osteoarthritis, knee